Octreotide LAR (R) treatment throughout pregnancy in an acromegalic woman

We report a 24-year-old woman with active acromegaly despite pituitary surg ery and irradiation who received continuous octreotide LAR(R) treatment for the control of GH excess throughout her pregnancy. The patient delivered a healthy girl following an uneventful pregnancy. Despite a substantial mate rno-fetal transfer of octreotide, postnatal development was normal with len gth parameters around the 50th percentile at 3 months of age. In almost all previously described cases (n=13) octreotide was stopped after the diagnos is of pregnancy was established. No side-effects of mother or fetus have be en reported. Octreotide treatment in pregnancy seems to be feasible and saf e. Due to the still-limited number of reported cases, the potential benefit s of octreotide treatment should be weighed carefully against its possible risks.